Kronos Bio (NASDAQ:KRON) Announces Earnings Results

Kronos Bio (NASDAQ:KRON) issued its earnings results on Tuesday. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.13), Zacks reports. Kronos Bio had a negative return on equity of 64.55% and a negative net margin of 867.66%.

Kronos Bio Trading Down 1.7 %

NASDAQ:KRON traded down $0.02 during mid-day trading on Tuesday, reaching $0.93. The company’s stock had a trading volume of 133,272 shares, compared to its average volume of 270,226. Kronos Bio has a 12-month low of $0.69 and a 12-month high of $1.60. The firm’s fifty day moving average price is $0.98 and its two-hundred day moving average price is $0.96. The stock has a market cap of $56.26 million, a P/E ratio of -0.65 and a beta of 1.79.

About Kronos Bio

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.